New In-Demand Market Research Report on Companion Diagnostics and its Future Now Available at MarketPublishers.com06 Oct 2011 • by Natalie Aster
LONDON – Companion diagnostics are diagnostic tests that are linked to a particular drug/therapy. This is a small, emerging market at present, but one of the fastest growing segments in the IVD market. The concept of a drug-diagnostic combination is not new, but has only started to garner interest, with the move of healthcare towards personalised medicine. The global value of the companion diagnostics market is projected to be worth $1.57bn in 2011. A number of specialty drugs will be associated with a companion diagnostic test by 2021, increasing the global market for companion diagnostics.
New market research study “Companion Diagnostics: World Market Outlook 2011-2021” provided by Visiongain has been recently published by Market Publishers Ltd.
Title: Companion Diagnostics: World Market Outlook 2011-2021
Published: August, 2011
Price: US$ 2,461
The research provides a detailed and all-covering review of the global companion diagnostics market. It analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities.
1. EXECUTIVE SUMMARY
1.1 Companion Diagnostics Market Review
1.2 Aims, Scope and Format of the Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods
2. INTRODUCTION TO COMPANION DIAGNOSTICS
2.1 Changing Paradigms of Treatment
2.2 What is Personalised Medicine?
2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine
2.3.1 What are In Vitro Diagnostic (IVD) Tests?
2.3.2 How IVDs Help Provide Personalised Treatment
2.4 Companion Diagnostics: Tools for Personalised Medicine
2.4.1 Theranostics: A Subset of Companion Diagnostics
2.5 Biomarkers to Companion Diagnostics
2.5.1 Genomic Biomarkers
2.5.2 Genomic Biomarkers in Oncology
2.6 Development of Companion Diagnostics
3. THE WORLD COMPANION DIAGNOSTICS MARKET, 2010-2021
3.1 Scope and Limitations
3.2 Total Companion Diagnostics Market was Worth $1.30bn in 2010
3.3 Sales Forecast for Total Companion Diagnostics Market, 2010-2015
3.4 Sales Forecast for Total Companion Diagnostics Market, 2016-2021
3.5 Companion Diagnostics is One of the Fastest Growing Segments in the IVD Market
3.5.1 Companion Diagnostics Gaining Greater Share of the IVD Market
3.6 Theranostics Constituted 31.5% of the Companion Diagnostics Market in 2010
3.7 Strong Growth in the Theranostics Market, 2011-2021
3.7.1 Theranostics Gaining Greater Share of the Companion Diagnostics Market, 2011-2021
4. LEADING NATIONAL MARKETS FOR COMPANION DIAGNOSTICS, 2010-2021
4.1 Leading National Markets for Companion Diagnostics, 2010
4.2 Leading National Markets for Companion Diagnostics: Sales Forecast, 2011-2021
4.2.1 The US Companion Diagnostics Market, 2011-2021
4.2.2 The Leading European Companion Diagnostics Markets, 2011-2021
4.2.3 The Japanese Companion Diagnostics Market, 2011-2021
4.2.4 Emerging-Economy Companion Diagnostics Markets
More new market research reports by the publisher can be found at Visiongain page.
The Market Publishers, Ltd.
Mrs. Tanya Rezler
Tel: +44 208 123 2220
Fax: +44 207 900 3970